Clinical trials: Glaucoma, Open-Angle Glaucoma Eye
Ocular Hypertension, Open Angle Glaucoma
Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension
The aim of this research study is to assess the safety and feasibility of lowering intraocular pressure (IOP) using an experimental study drug, JV-GL1.
- Trial name
- NCT04761705
- Testing
- JV-GL1, Latanoprost 0.005% Ophthalmic Solution
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- JeniVision, Inc.
Glaucoma, Ocular Hypertension
A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG
The purpose of this study is to evaluate the safety and preliminary efficacy of two formulations of the Latanoprost-PPDS in subjects with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT00967811
- Testing
- Formulation E1 of L-PPDS, Formulation E2 of L-PPDS
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Mati Therapeutics Inc.
Eye Diseases, Glaucoma, Open-Angle
Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)
Prospective, unmasked, randomized evaluation of the iStent in patients with primary open-angle glaucoma. Patients will be randomized to one of two groups: 1) iStent, or 2) medication.
- Conditions
- Eye Diseases, Glaucoma, Open-Angle, Glaucoma
- Trial name
- SL (NCT00913029)
- Testing
- iStent, latanoprost/timolol
- Where
- 16 sites in Armenia, Austria and 7 more
- Volunteers
- 192 people
- Sponsor
- Glaukos Corporation
Primary Open Angle Glaucoma
Multicenter Ab-interno Glaucoma Study Investigating Canaloplasty
A prospective, multicenter, randomized, single-masked clinical trial to evaluate the effectiveness outcomes of canaloplasty performed as a standalone procedure with the iTrack microcatheter to the Omni surgical system, and to…
- Trial name
- MAGIC (NCT04769453)
- Testing
- Canaloplasty using the iTrack microcatheter with Healon GV Pro, Canaloplasty using the Omni surgical system with Healon GV Pro, Canaloplasty using the iTrack microcatheter with Healon Pro
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Nova Eye, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy
This is an observational study of patients diagnosed with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) who are insufficiently responsive to monotherapy and who are prescribed GANfort® (fixed combination of 0.3…
- Trial name
- NCT01628601
- Testing
- Fixed combination 0.3 mg bimatoprost and 5 mg timolol
- Where
- Austria
- Volunteers
- 392 people
- Sponsor
- Allergan
Glaucoma, Open-Angle
Negative Pressure Applied by the Equinox MPD for Severe Open Angle Glaucoma
This is a prospective, non-significant risk, controlled, randomized, multi-center, masked, feasibility study to evaluate the safety and IOP-lowering effectiveness of negative pressure application (via the Mercury MPD) for…
- Trial name
- NCT04632329
- Testing
- Negative Pressure Treatment via the Mercury Multi-Pressure Dial
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Equinox
Glaucoma
Open Label Extension of LipoLat-CS202
This is an open-label, observational extension of patients who received POLAT-001 in LipoLat-CS202.
- Trial name
- NCT02599688
- Testing
- Observation only
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Peregrine Ophthalmic
Primary Open Angle Glaucoma
Hydrus® Microstent New Enrollment Post-Approval Study
The purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation.
- Trial name
- CONFIRM (NCT04553523)
- Testing
- Hydrus Microstent, Cataract surgery, Monofocal IOL
- Where
- 22 sites in United States
- Volunteers
- 545 people
- Sponsor
- Alcon Research
Glaucoma, Open Angle Glaucoma
A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension
PhXA41 is not inferior to timolol
- Conditions
- Glaucoma, Open Angle Glaucoma, Ocular Hypertension
- Trial name
- NCT00751127
- Testing
- PhXA41, timolol
- Where
- 17 sites in United States
- Volunteers
- 268 people
- Sponsor
- Pfizer
Primary Open-angle Glaucoma (POAG), Ocular Hypertension (OHT)
Safety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma and Ocular Hypertension
The primary purpose of this study is to investigate the safety and efficacy of bilateral DWT in subjects with POAG or OHT compared to active and sham controls.
- Trial name
- NCT02226094
- Testing
- DWT device dose A, Ellex Tango SLT machine, DWT device dose B
- Where
- 2 sites in Philippines
- Volunteers
- 35 people
- Sponsor
- OcuTherix, Inc.
Open-Angle Glaucoma, Ocular Hypertension
A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%
The purpose of this study was to describe the ocular discomfort immediately upon instillation of Brinzolamide 1%/Brimonidine 0.2% Tartrate Ophthalmic Suspension, Brinzolamide 1% Ophthalmic Suspension, and Brimonidine Tartrate…
- Trial name
- NCT01426867
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, Brimonidine tartrate ophthalmic solution, 0.2%
- Volunteers
- 103 people
- Sponsor
- Alcon Research
Open Angle Glaucoma, Ocular Hypertension
Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%
A multi-center, observer-masked, randomized, parallel group efficacy and safety study of TRAVATAN® versus a new formulation of Travoprost Ophthalmic Solution, 0.004%
- Trial name
- NCT01452009
- Testing
- Travoprost Ophthalmic Solution, 0.004% (New Formulation), TRAVATAN®
- Sponsor
- Alcon Research
Glaucoma Open-Angle Primary, Ocular Hypertension
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 [0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.
- Trial name
- NCT05913232
- Testing
- H-1337 0.6%, H-1337 1.0%, Timolol 0.5%
- Where
- 9 sites in United States
- Volunteers
- 201 people
- Sponsor
- D. Western Therapeutics Institute, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)
This study will evaluate assessments from the Goniometric Lens compared with those from anterior segment imaging in patients with open-angle glaucoma (OAG) and/or ocular hypertension (OHT).
- Trial name
- NCT01540370
- Testing
- No Treatment
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma
The Effects of Visior on Ocular Hemodynamics
To determine the relationship between the affects of viewing commercially available content through the VISIOR video goggles and ocular blood flow in glaucoma patients and healthy subjects.
- Trial name
- NCT02959593
- Testing
- VISIOR video goggles
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Visior Technologies Ltd.
Open Angle Glaucoma (OAG), Ocular Hypertension (OHT)
iDose TR Administration in an Office-Based Surgery Setting
Clinical in-use observational trial to evaluate the administration of iDose TR (travoprost intracameral implant) in an office-based surgery setting.
- Trial name
- NCT07816692
- Testing
- iDose TR (travoprost intracameral implant) 75 µg
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Glaukos Corporation
Ocular Hypertension, Open Angle Glaucoma
Study of AR-13324 in Patients With Elevated Intraocular Pressure
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days.
- Trial name
- NCT01528787
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 11 sites in United States
- Volunteers
- 85 people
- Sponsor
- Aerie Pharmaceuticals
Open-angle Glaucoma or Ocular Hypertension
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to investigate the safety and efficacy of four concentrations of DE-117 ophthalmic solution.
- Trial name
- NCT01868126
- Testing
- DE-117 ophthalmic solution, latanoprost ophthalmic solution
- Where
- 7 sites in United States
- Volunteers
- 91 people
- Sponsor
- Santen Inc.
Open Angle Glaucoma, Ocular Hypertension
A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma
To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.
- Trial name
- NCT00277498
- Testing
- Xalacom, Xalatan, Timolol
- Where
- 64 sites in United States
- Volunteers
- 528 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open-Angle, Glaucoma, Narrow Angle
Study of a Cilioscleral Interposition Device (CID) SV22 in Patients With Primary Open Angle Glaucoma and Narrow Angle Glaucoma
The purpose of this study is to evaluate the safety and effectiveness of implanting a new version of an interposition supraciliary implant (SV22) as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with…
- Trial name
- SAFARI 3 (NCT05236439)
- Testing
- Interposition supraciliary implant
- Where
- Armenia
- Volunteers
- 57 people
- Sponsor
- Ciliatech